Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases

@article{Capper2011ImmunohistochemicalTO,
  title={Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases},
  author={David Capper and Anna Sophie Berghoff and Manuel Magerle and Ayseg{\"u}l Ilhan and Adelheid W{\"o}hrer and Monika Hackl and Josef Pichler and Stefan Pusch and Jochen Meyer and Antje Habel and Peter Petzelbauer and Peter Birner and Andreas von Deimling and Matthias Preusser},
  journal={Acta Neuropathologica},
  year={2011},
  volume={123},
  pages={223-233}
}
Brain metastases (BM) are frequent and carry a dismal prognosis. BRAF V600E mutations are found in a broad range of tumor types and specific inhibitors targeting BRAF V600E protein exist. We analyzed tumoral BRAF V600E-mutant protein expression using the novel mutation-specific antibody VE1 in a series of 1,120 tumor specimens (885 BM, 157 primary tumors, 78 extra-cranial metastases) of 874 BM patients. In 85 cases, we performed validation of immunohistochemical results by BRAF exon 15 gene… 
Frequency of BRAF V600E mutations in 969 central nervous system neoplasms
TLDR
Routine screening for BRAF V600E mutations for glioblastomas WHO grade IV below the age of 30 is suggested, especially in gliOBlastomas with epithelioid features and in all rhabdoid meningiomasWHO grade III.
Expression of BRAF V600E Mutant Protein in Epithelial Ovarian Tumors
TLDR
For reliable assessment of the BRAF V600E status in ovarian epithelial tumor samples, an integrated approach using immunohistochemistry and genetic analysis seems advisable, as both methods lead to incorrect results in some cases.
Lack of BRAF V600E Protein Expression in Primary Central Nervous System Lymphoma
TLDR
Evidence is provided that the BRAF V600E mutation is not pathobiologically relevant in PCNSL and as a consequence is not a feasible drug target in this tumor type.
Assessment of BRAF V600E (VE1) protein expression and BRAF gene mutation status in codon 600 in benign and malignant salivary gland neoplasms
TLDR
In studied salivary gland cancers, no PCR-based prove mutations of BRAF V600 were detected and further molecular analyses are necessary to rapid molecular arrays for the identification of specific mutations, optimal for individualized targeted therapies.
BRAF V600E Expression by Immunohistochemistry in Colon Cancer and Clinico-pathologic Features Associated with BRAF-Mutated Colonic Cancers in Mexican Patients
TLDR
IHC against BRAF V600E showed an excellent performance, making it feasible as an alternative for molecular examination, and tumors with BRAF mutated did not show distinctive clinico-pathological characteristics, except for a larger tumor size.
Assessment of BRAF V600E Status in Colorectal Carcinoma: Tissue-Specific Discordances between Immunohistochemistry and Sequencing
TLDR
VE1 IHC produces suboptimal results in colorectal carcinoma and should not be used to guide patient management, as well as being highly concordant with sequencing results.
Clinical neuropathology practice news 2-2012: BRAF V600E testing
TLDR
BRAF V600E testing is clinically indicated in relatively few cases of the daily clinical neuropathology practice, but has important predictive implications for patients with melanoma brain metastases.
Detection of the BRAF V600E Mutation in Colon Carcinoma: Critical Evaluation of the Imunohistochemical Approach
TLDR
Although VE1 antibody can be useful in the screening of colon carcinomas for BRAF V600E-mutant proteins, molecular genetic confirmation is always necessary for mutation diagnosis and only strong positivity should be considered when using the VE 1 antibody and Leica Bond-Max automated immunohistochemistry.
BRAF V600E Immunohistochemistry Is Reliable in Primary and Metastatic Colorectal Carcinoma Regardless of Treatment Status and Shows High Intratumoral Homogeneity
TLDR
BRAF V600E IHC is reliable for the evaluation of mutational status in colorectal carcinoma regardless of site or prior treatment history, and staining shows a high degree of intratumoral homogeneity.
Diagnostic value of immunohistochemistry for the detection of the BRAF V600E mutation in colorectal carcinoma.
TLDR
The data show that IHC could be used in routine clinical practice as a screening method for BRAF V600E mutant protein detection in CRC patients.
...
...

References

SHOWING 1-10 OF 27 REFERENCES
Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody
TLDR
The development of a monoclonal BRAF V600E mutation-specific antibody that can differentiate BRAFV600E and wild type protein in routinely processed formalin-fixed and paraffin-embedded tissue is described.
Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma
TLDR
The high mutation frequencies in pleomorphic xanthoastrocytomas, gangliogliomas and extra-cerebellar pilocytic astrocyTomas implicate BRAFV600E mutation as a valuable diagnostic marker for these rare tumor entities.
Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations.
  • P. Paik, M. Arcila, Gregory Riely
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2011
TLDR
BRAF mutations occur in 3% of patients with lung adenocarcinoma and occur more commonly in current and former smokers, which is significantly higher in lung cancer than in melanoma.
NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing
TLDR
The separate genotypes of BRAF and NRAS were associated with differences in several key clinical and pathological parameters, indicating differences in the biology of melanoma tumours with different proto-oncogene mutations.
Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
  • G. Long, A. Menzies, R. Kefford
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2011
TLDR
The presence of mutant BRAF had no impact on the disease-free interval from diagnosis of first-ever melanoma to first distant metastasis; however, it may have impacted survival thereafter.
Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma.
TLDR
The apparent restriction of these BRAF and KRAS mutations to low-grade serous ovarian carcinoma and its precursors suggests that low- grade and high-grade ovarian serous carcinomas develop through independent pathways.
Characterization of R132H Mutation‐specific IDH1 Antibody Binding in Brain Tumors
TLDR
Investigation of the capability of this antibody to differentiate wild type and mutated IDH1 protein in central nervous system (CNS) tumors by Western blot and immunohistochemistry finds the ability of mIDH1R132H to detect single infiltrating tumor cells intriguing.
Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma
TLDR
The data indicate that BRAF gene mutations are a relatively common event in CC but not in HCC, and disruption of the Raf/MEK/ERK (MAPK) kinase pathway was detected in approximately 62% of all CC and is therefore one of the most frequent defects in cholangiocellular carcinogenesis.
Value and Limitations of Immunohistochemistry and Gene Sequencing for Detection of the IDH1-R132H Mutation in Diffuse Glioma Biopsy Specimens
TLDR
The data confirm anti-IDH1-R132H immunostaining as a reliable method for evaluation of IDH1 gene mutation status and suggest the following: in some cases, nonspecific background staining or regional heterogeneity of IDh1- R132H protein expression may necessitate confirmatory genetic analysis.
Inhibition of mutated, activated BRAF in metastatic melanoma.
TLDR
Treatment of metastatic melanoma with PLX4032 in patients with tumors that carry the V600E BRAF mutation resulted in complete or partial tumor regression in the majority of patients.
...
...